ChiCTR2500100172 版本V1.0 版本创建时间2025/04/03 11:57:46 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500100172 

最近更新日期:

Date of Last Refreshed on:

2025-04-03 11:57:29 

注册时间:

Date of Registration:

2025-04-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

内镜下丙泊酚注射痛与达到同等镇静深度时丙泊酚镇静剂量关系的临床研究

Public title:

Clinical study on the relationship between pain during propofol injection under endoscopy and the dose of propofol required to achieve the same depth of sedation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

内镜下丙泊酚注射痛与达到同等镇静深度时丙泊酚镇静剂量关系的临床研究

Scientific title:

Clinical study on the relationship between pain during propofol injection under endoscopy and the dose of propofol required to achieve the same depth of sedation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

袁霞 

研究负责人:

詹莉 

Applicant:

Yuan Xia 

Study leader:

Zhan Li 

申请注册联系人电话:

Applicant telephone:

+86 136 5768 8415

研究负责人电话:

Study leader's
telephone:

+86 133 5034 9211

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

405084258@qq.com

研究负责人电子邮件:

Study leader's E-mail:

798047503@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝北区回兴街道双湖支路1号

研究负责人通讯地址:

重庆市渝北区回兴街道双湖支路1号

Applicant address:

No.1, Shuanghu Branch Road, Huixing Street, Yubei District, Chongqing municipality

Study leader's address:

No.1, Shuanghu Branch Road, Huixing Street, Yubei District, Chongqing municipality

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第三医院

Affiliation of the Leader:

The Third Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年科伦审第(62)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第三医院伦理委员会

Name of the ethic committee:

The Ethics Committee of the Third Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-17 00:00:00

伦理委员会联系人:

陈帅

Contact Name of the ethic committee:

Chen Shuai

伦理委员会联系地址:

重庆市渝北区回兴街道双湖支路1号

Contact Address of the ethic committee:

No.1, Shuanghu Branch Road, Huixing Street, Yubei District, Chongqing municipality

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 6716 7736

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第三医院

Primary sponsor:

The Third Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝北区回兴街道双湖支路1号

Primary sponsor's address:

The Third Affiliated Hospital of Chongqing Medical University

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第三医院

具体地址:

重庆市渝北区回兴街道双湖支路1号

Institution
hospital:

The Third Affiliated Hospital of Chongqing Medical University

Address:

No.1, Shuanghu Branch Road, Huixing Street, Yubei District, Chongqing municipality

经费或物资来源:

无经费

Source(s) of funding:

NO

研究疾病:

丙泊酚注射痛  

Target disease:

Pain on propofol injection

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究通过对丙泊酚注射痛的临床观察,寻找并分析POPI与丙泊酚诱导剂量之间的的量效关系。在丙泊酚为镇静剂的诱导过程中,让麻醉医生可以在药物注射过程中根据患者的注射部位疼痛与否及疼痛程度适当调整丙泊酚的剂量,以达到精准麻醉的目的。  

Objectives of Study:

In this study, we sought and analyzed the dose-effect relationship between POPI and propofol induced dose through clinical observation of propofol injection pain. In the induction process of propofol as a sedative, the anesthesiologist can adjust the dose of propofol according to the pain at the injection site and the pain degree during the drug injection, so as to achieve the purpose of precise anesthesia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18~60岁的患者; 2.常规接受上消化道内镜检查; 3.ASA分级:I级或II级; 4.体重指数大于18 kg/m^2且小于28 kg/m^2(肥胖); 5.静脉注射部位为手背或前臂(留置针大小与部位); 6.自愿签署麻醉知情同意书。

Inclusion criteria

1. Patients aged from 18 to 60 years old; 2. Routine acceptance of upper gastrointestinal endoscopy; 3. ASA grade: Grade I or Grade II; 4. Body mass index is greater than 18 kg/m^2 and less than 28 kg / m^2 (obesity); 5. The intravenous injection site is the back of the hand or the forearm (the size and site of the indwelling needle) 6. Voluntary signing of the informed consent form for anesthesia.

排除标准:

1.有常规内镜操作禁忌证或拒绝麻醉的患者; 2.病情未得到适当控制的可能威胁生命的循环、呼吸系统疾病、活动性大出血伴休克等; 3.肝功能障碍(Child-Pugh C级以上)、胃肠道梗阻、感冒发热、支气管哮喘、近1个月发生严重的神经系统疾病者等; 4.焦虑/抑郁; 5.有吸毒病史或这酗酒史; 6.评估明确困难气道的患者、病态肥胖以及确诊的阻塞性睡眠呼吸暂停患者不能在门诊完成无痛胃镜检查; 7.无人陪伴者; 8.丙泊酚过敏或禁忌症者; 9.孕妇。

Exclusion criteria:

1. Patients with a contraindication for conventional endoscopic procedures or for refusing anesthesia. 2. Life-threatening circulation, respiratory diseases, active massive bleeding with shock, etc., where the condition is not properly controlled. 3. Liver dysfunction (Child-Pugh C or above), gastrointestinal obstruction, cold fever, bronchial asthma, severe neurological diseases in the past month, etc. 4. Anxiety / depression; 5. Having a history of drug use or such alcohol abuse; 6. The evaluation of patients with a clear difficult airway, patients with morbid obesity and confirmed obstructive sleep apnea can not complete the painless gastroscopy in the outpatient clinic. 7. Unaccompanied people. 8. Patients with allergy or contraindications to propofol; 9. Pregnant women.

研究实施时间:

Study execute time:

From 2025-05-01 00:00:00 To 2026-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-05-01 00:00:00 To 2026-12-30 00:00:00

干预措施:

Interventions:

组别:

POPI组与非POPI组

样本量:

300

Group:

POPI VS no-POPI

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆市 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第三医院 

单位级别:

三甲 

Institution
hospital:

The Third Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

丙泊酚注射痛

指标类型:

主要指标

Outcome:

Pain on propofol injection

Type:

Primary indicator

测量时间点:

静脉注射丙泊酚时

测量方法:

疼痛NRS评分

Measure time point of outcome:

at the time of receiving propofol i. v

Measure method:

Numerical Rating Scale

指标中文名:

丙泊酚总量

指标类型:

主要指标

Outcome:

Total dose of propofol

Type:

Primary indicator

测量时间点:

胃镜结束时

测量方法:

读注射器刻度

Measure time point of outcome:

At the end of gastroscopy

Measure method:

Read syringe scale

指标中文名:

血氧饱和度

指标类型:

次要指标

Outcome:

blood oxygen saturation

Type:

Secondary indicator

测量时间点:

麻醉前至麻醉结束时,每隔5分钟

测量方法:

监护仪

Measure time point of outcome:

Every 5 min intervals until the end of anesthesia

Measure method:

Monitor

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

麻醉前至麻醉结束时,每隔5分钟

测量方法:

监护仪

Measure time point of outcome:

Every 5 min intervals until the end of anesthesia

Measure method:

Monitor

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

麻醉前至麻醉结束时,每隔5分钟

测量方法:

监护仪

Measure time point of outcome:

Every 5 min intervals until the end of anesthesia

Measure method:

Monitor

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

由主管麻醉的医师采集数据并填写电子表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data was collected by the anesthesia physician and filled in the electronic form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-04-03 11:57:29